Story no.231OngoingHealthNotableCôte-d'Or +228 Oct → 14 Nov20 facts · 78 art.

Anti-obesity GLP-1 in France: reimbursement, off-label use and health alerts

Early November 2026, the testimony of a patient treated with Mounjaro and the limits of reimbursement for anti-obesity treatments in Dijon open the file, while a survey indicates that one in five French people would be ready to use GLP-1s to lose weight. The appetite suppressant market is growing strongly and side effects are multiplying, customs strengthening controls against trafficking of products such as Wegovy. The health risks of Ozempic and Wegovy are highlighted, and the 100 million euro envelope for reimbursement is deemed insufficient. Influencers are accused of diverting these medications, patients turn to parallel markets and a former obese person warns about Wegovy. Health professionals launch an alert on weight-loss injections, then a Lilly France campaign against grossophobia is suspected of disguised advertising for Mounjaro.

In brief

Ongoing story bringing together 20 events nationwide, followed from 28 October 2026 to 14 November 2026. 78 articles from 23 sources (health); last updated on 14 November 2026 at 09:00.

Who is covering it, and from what angle

Method

15Left23 %

47Centre72 %

3Right5 %

65 articles of rated outlets · 13 unrated outside the bar · 23 sources (78 art.) · the three sides talk about it · outlets: left 5, centre 15, right 2

Angle comparison for the whole story

The three sides cover the same file (arrival of Wegovy in tablet form, French enthusiasm, risks and trafficking), but differ by angle: the left favors personal testimonies and individual health risks, the center widely presents the Ifop survey and practical alerts, the right highlights the explosion of the appetite suppressant market, side effects and economic and regulatory aspects.

Left

Highlights personal testimonies (patient who lost weight without medication, former obese person warning about Wegovy), health risks linked to off-label use and recourse to parallel markets, as well as changes in eating habits.

Centre

Widely presents the Ifop survey (one in five French people tempted, even without being obese), health professional alerts on injections and harmful substances, influencers diverting medications and customs controls against trafficking.

Right

Highlights the explosion of the appetite suppressant market and the multiplication of side effects, the non-reimbursable nature of oral Wegovy, consultation waiting times and the economic aspects of treatment.

Written by an AI from headlines and extracts only of all events in the story · 14 Nov, 15h44

What is established

Method

Confirmed by several sources(5)

7
Oral Wegovy is marketed in France from 2 November.
7 independent sourcesBFMTV / RMC, Paris-Normandie, Midi Libre, 20 Minutes, La Dépêche du Midi +4
5
Oral Wegovy is sold at the recommended price of 169 euros per month and is not reimbursed.
5 independent sourcesMidi Libre, Le Moniteur des pharmacies, 20 Minutes, Libération, Les Échos
2
Waiting times in specialized consultations authorized to prescribe anti-obesity medications reach up to 18 months.
2 independent sourcesLes Échos, Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain
2
Oral Wegovy contains semaglutide, a GLP-1 receptor agonist.
2 independent sourcesParis-Normandie, TF1 Info / LCI
2
Injectable Wegovy has been available in France since 2024 and reimbursed under conditions since June 2026.
2 independent sourcesLe Progrès, TF1 Info / LCI

Single source so far(5)

The European Commission authorized oral Wegovy on 15 July 2026. (according to Paris-Normandie)
A parallel market for these medications thrives, difficult to quantify. (according to Le Progrès, Le Bien Public, Le Dauphiné libéré, L'Est Républicain)
Professor Emmanuel Disse declared: "The more patients are treated, the more there will be bariatric surgery." (according to Le Progrès, Le Bien Public, L'Est Républicain)
Meta Tshiteya, treated with Mounjaro for three years, lost 50 kg. (according to L'Est Républicain, Le Dauphiné libéré, Le Progrès)

AI cross-check of the headlines and extracts of 28 articles (18 outlets) · “confirmed” = reported by at least two independent outlets · 1 Nov, 22h41

Checked on the web(3)

Not confirmed at this stage
Oral Wegovy is marketed in France from 2 November.
Sources: ansm.sante.fr(official), www2.assemblee-nationale.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr
1 Nov, 22h44
Not confirmed at this stage
Oral Wegovy is sold at the recommended price of 169 euros per month and is not reimbursed.
Sources: ansm.sante.fr(official), rtl.fr, franceinfo.fr, lagazettefrance.fr, prescrire.org
1 Nov, 22h44
Not confirmed at this stage
The European Commission authorized oral Wegovy on 15 July 2026.
Sources: lagazettefrance.fr, prescrire.org, ameli.fr, qare.fr, 20minutes.fr
1 Nov, 22h44

Automatic web search, official sources first · “contradicted” only when an official source is cited

Timeline

newest first

Outlets:LeftCentreRightUncategorised· badge = severity

11h05
Une campagne anti-grossophobie de Lilly France soupçonnée de publicité déguisée pour le Mounjaro
Un spot télévisé contre la grossophobie est diffusé par Lilly France, filiale du laboratoire fabriquant le Mounjaro, traitement anti-obésité remboursé depuis juin. La campagne de sensibilisation est jugée proche de la publicité pour ce médicament.
franceinfoUncategorised

In figures

The activity

20 faits

Latest activity 9 hours ago

1 3 3 3 2 4 1 1 2

28 Oct14 Nov

Affected departments

National

Reported toll

Amounts cited169 euros · 235 euros · 100 millions

Highest number recorded in 6 article(s), automatically extracted: please check sources.